Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Abbott licenses development, marketing rights to Theragyn from Antisoma

Oct. 29, 1999

Clinical data presented for Avax's autologous cancer vaccines

Oct. 29, 1999

Vical receives orphan drug status for Allovectin-7

Oct. 28, 1999

StessGen begins trial of HspE7 for anal dysplasia

Oct. 27, 1999

Development of OvaRex is now sole focus for AltaRex

Oct. 26, 1999

Human trials initiated for IL-13 cytotoxin under development by NeoPharm

Oct. 20, 1999

AltaRex reports new partnering plans for OvaRex MAb

Oct. 19, 1999

ImmunoGen presents positive pharmacokinetic data for huC242-DM1/SB-408075

Oct. 19, 1999

Neurocrine Biosciences' NBI-3001 granted fast track designation

Oct. 18, 1999

Immune Response reports data from phase I colon cancer vaccine study

Oct. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...